Teleflex (NYSE:TFX) Updates FY 2025 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 13.200-13.600 for the period, compared to the consensus estimate of 14.090. The company issued revenue guidance of $3.1 billion-$3.1 billion, compared to the consensus revenue estimate of $3.1 billion.

Teleflex Trading Up 0.3 %

Shares of Teleflex stock opened at $126.30 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The business has a fifty day simple moving average of $135.82 and a two-hundred day simple moving average of $170.78. Teleflex has a 1 year low of $124.66 and a 1 year high of $249.91. The company has a market capitalization of $5.86 billion, a price-to-earnings ratio of 25.11, a P/E/G ratio of 1.73 and a beta of 1.19.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $700.67 million for the quarter, compared to analyst estimates of $699.37 million. During the same period in the prior year, the firm earned $3.21 earnings per share. The company’s revenue was down 5.0% on a year-over-year basis. Research analysts forecast that Teleflex will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.08%. The ex-dividend date was Friday, March 7th. Teleflex’s payout ratio is 95.77%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Bank of America downgraded Teleflex from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $235.00 to $140.00 in a research note on Tuesday, March 4th. Raymond James downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Citizens Jmp cut shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Morgan Stanley decreased their target price on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $140.00 price target (down from $255.00) on shares of Teleflex in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Teleflex has an average rating of “Hold” and a consensus price target of $167.25.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.